CLLS
Cellectis S.A. (NASDAQ)
Healthcare — Biotechnology
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL). It also develops ALPHA3, targets Large B-Cell Lymphoma (LBCL); TRAVERSE, for the treatment of patients with advanced or metastatic clear cell renal cell carcinoma (RCC). In addition, the company Melanoma, for treatment of unresectable or metastatic melanoma. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
Price History
Fundamentals
| Market Cap | $295.80M |
| P/E Ratio (TTM) | - |
| Forward P/E | -4.74 |
| EPS (TTM) | $-0.67 |
| Dividend Yield | - |
| Profit Margin | -89.51% |
| Revenue Growth | -37.30% |
| ROE | -76.34% |
| Debt/Equity | 137.41 |
| Recommendation | None |
| Analyst Target | $7.60 |
| Analysts | 5 |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 38.5 |
| Beta | 2.75 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $5.48 |
| 52-Week Low | $1.56 |
| 50-Day Avg | $3.48 |
| 200-Day Avg | $3.82 |
| Avg Volume | 32.1K |
| Volume | 1.7K |
Performance Analysis
BEARISHCLLS is flashing more cautionary signals — investors should monitor closely.
Recent News
Last updated: Jul 02, 2026 13:03 UTC
Back to Screener Export Report